Similarly, as first-line treatment for advanced NSCLC, the combination of the personalized neoantigen vaccine NEO-PV-01 with pemetrexed, carboplatin, and pembrolizumab induced neoantigen-specific CD4+ and CD8+ T cell anti-tumor responses without treatment-related serious adverse events [153]. The gene discussed is CD8A; the disease is neoplasm.